Compare · IQV vs MDT
IQV vs MDT
Side-by-side comparison of IQVIA Holdings Inc. (IQV) and Medtronic plc. (MDT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. IQV focuses on Biotechnology: Commercial Physical & Biological Resarch, while MDT focuses on Biotechnology: Electromedical & Electrotherapeutic Apparatus.
- MDT is the larger of the two at $131.60B, about 3.0x IQV ($43.63B).
- MDT has been more active in the news (14 items in the past 4 weeks vs 8 for IQV).
- Both have 25 recent analyst ratings on file.
- Company
- IQVIA Holdings Inc.
- Medtronic plc.
- Price
- -
- -
- Market cap
- $43.63B
- $131.60B
- 1M return
- -
- +8.58%
- 1Y return
- -
- +6.78%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NYSE
- IPO
- 2013
- News (4w)
- 8
- 14
- Recent ratings
- 25
- 25
IQVIA Holdings Inc.
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Latest IQV
- Officer Sherbet Eric exercised 8,436 shares at a strike of $131.82, sold $1,239,678 worth of shares (4,446 units at $278.83) and returned $1,112,173 worth of shares to the company (3,990 units at $278.74) (SEC Form 4)
- Director Wims Morris Leslie was granted 125 deferred shares (SEC Form 4)
- Director Goggins Colleen A was granted 144 deferred shares (SEC Form 4)
- Director Fasano Jim was granted 154 deferred shares (SEC Form 4)
- Director Danhakl John G was granted 134 deferred shares (SEC Form 4)
- SEC Form 10-Q filed by IQVIA Holdings Inc.
- SEC Form 8-K filed by IQVIA Holdings Inc.
- IQVIA Reports Third-Quarter 2026 Results
- IQVIA Selects Veeva Clinical Operations Applications
- IQVIA Launches IQVIA Explorer to Help Life Sciences Companies Make Better Commercial Decisions
Latest MDT
- Orchestra BioMed to Participate in the Piper Sandler 38th Annual Healthcare Conference
- Medtronic upgraded by Piper Sandler with a new price target
- Medtronic announces FDA clearance of general surgery procedures for the Hugo™ robotic-assisted surgery (RAS) system
- Medtronic to acquire Contego Medical, expanding access to next-generation carotid therapies
- Orchestra BioMed Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
- SEC Form SCHEDULE 13G filed by Medtronic plc.
- Imperative Care Announces Two New Board of Directors Appointments
- Orchestra BioMed Announces Pricing of Public Offering
- Orchestra BioMed Announces Proposed Public Offering
- President Marinaro Michael was granted 6,547 units of Ordinary Shares, increasing direct ownership by 6% to 113,353 units (SEC Form 4)